Biohaven 2026: Revenue ($129.3M), Net income ($129.28M), EPS ($0.86) — 10-Q Summary

Biohaven Ltd. reported a net loss of $129.28M for 2026, with diluted loss per share of $0.86, narrowing from 2025. Revenue was $129.3M. The company reprioritized development in Kv7 epilepsy, immune degraders, and myostatin therapies. Key trials and licensing deals are ongoing.

Original reporting
Published Oct 29, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Biohaven 2026: Revenue ($129.3M), Net income ($129.28M), EPS ($0.86) — 10-Q Summary — source image
Decision brief

The 30-second read

$BHVNBearishLow
01

Why it matters

The loss and EPS miss suggest near‑term price weakness, but the pipeline progress may sustain longer‑term interest.

02

Market read

Primary earnings disclosure for a US‑listed biotech; new loss figures likely trigger short‑term sell‑off.

03

What to watch

Upcoming trial readouts for BHV‑1300 and BHV‑1400 could offset short‑term pain.

Relevance 7/10Novelty 7/10Timing: post‑market filing on Oct 29

Background

Biohaven's 10‑Q provides the first public disclosure of its Q4 2026 financial results and pipeline updates.

Company-level read

Ticker impact

$BHVNBearishHigh confidence
Context

Biohaven Ltd. filed its 10‑Q reporting a $129.3M comprehensive loss and $0.86 loss per share for Q4 2026, new financial data not previously public.

Expected impact

downward pressure as investors price in the larger-than‑expected loss

Evidence & confidence

Quarterly loss figures are fresh and materially worse than prior periods, a typical catalyst for short‑term sell‑off in biotech stocks.

Market effects

May weigh on other neuro‑degeneration and rare‑disease biotech peers.

Limited to US‑listed biotech investors.

Minimal global impact beyond sector.

Counterpoint

If the loss reflects strategic investment in pipeline assets, long‑term upside could remain.

Key entities

  • Biohaven Ltd.

    Biopharma focused on neurology and rare diseases.

Related articles

$BHVNMedAI 9/10

Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026

Biohaven (BHVN) presented Phase 1 data for BHV-1530, showing clinical activity in FGFR3-altered urothelial and head and neck cancers. 6 of 10 patients responded, with no severe side effects. Biohaven plans a pivotal study in 2027 for potential accelerated approval.

$BHVNMedAI 8/10

Biohaven Presents Pipeline Updates and Development Plans at Jefferies Healthcare Conference

Biohaven presented updates at the Jefferies Global Healthcare Conference, highlighting its drug-development programs in areas like epilepsy, obesity, and oncology. The company initiated a pivotal trial for BHV-1300 in Graves' disease and plans a pivotal trial for BHV-1400 in IgA nephropathy for 2026. Preliminary data showed rapid thyroid-hormone normalization in three participants.

$BHVNMedAI 8/10

Biohaven advances Graves’ disease drug trial, presents research

Biohaven Ltd. (BHVN) is advancing its Phase 3 trial for Graves' disease drug BHV-1300, enrolling 300 adults across multiple countries. The trial aims to restore normal thyroid function. BHV-1300 showed significant reductions in autoantibodies in a Phase 1b study. Biohaven also presented research at the American Thyroid Association meeting and secured an $80M upfront license deal with Ono Pharmaceutical.

$BHVNMedAI 8/10

Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting

Biohaven Ltd. (BHVN) is advancing its Graves' disease program with a Phase 3 trial of BHV-1300, enrolling at 55+ sites in the U.S., Canada, and other regions. The trial aims to restore normal thyroid function. BHV-1300 showed an 80% reduction in pathogenic autoantibodies in a Phase 1b study. Biohaven also presented three posters at the 2026 ATA Annual Meeting. Ono Pharmaceutical licensed BHV-1300 and related degraders for Asia, with Biohaven receiving $80M upfront.

$BHVNHighAI 9/10

Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results

Biohaven Ltd. (BHVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results • The US Food and Drug Administration (FDA) accepted new drug application resubmission for Vyglxia (troriluzole) in spinocerebeller ataxia (SCA), user fee goal date 1Q27. • Announc